Pilot Study of Imatinib (Gleevec) as Treatment for Advanced Thymic Carcinoma

Indiana University School of Medicine11 enrolled

Overview

This study is important to demonstrate if single agent activity is noted for patients with thymic tumors over expressing c-kit and/or PDGF. If this current trial is positive, it opens the door to evaluate other combination of drugs with imatinib in thymic tumors.

Thymic carcinomas are particularly more concerning due to their aggressive metastatic nature and shorter overall survival, in comparison to their lesser-malignant thymoma counterparts. This necessitates the need for systemic therapy. Due to the paucity of thymic carcinoma cases, the ideal regimen for locally advanced or metastatic thymic carcinomas is not defined.To this point, there has not been a study using imatinib in thymic tumors expressing the KIT tyrosine kinase protein or PDGF tyrosine kinase protein. This study is important to demonstrate if single agent activity is noted for patients with thymic tumors over expressing c-kit and/or PDGF. If this current trial is positive, it opens the door to evaluate other combination of drugs with imatinib in thymic tumors.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Thymic Carcinoma

Interventions

Gleevec (imatinib)DRUG

Imatinib 600mg po qd X 21 days.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Histological or cytological proof of advanced C-KIT positive or PDGFR positive thymic carcinoma. For protocol purposes, advanced disease is defined as disease * Patient must have at least one documented measurable lesion obtained by imaging within 28 days prior to being registered for protocol therapy. * No prior imatinib therapy. * Age \> 18 years at the time of consent * ECOG performance status of 0 or 1 * ANC ≥ 1500/mm3,Platelet count ≥ 100,000/mm,Total bilirubin \< 1.5ULN,3.10 Serum creatinine ≤ 1.7 mg/dl,ALT and AST ≤ 3 x ULN Exclusion Criteria: * Clinically significant infections as judged by the treating investigator * Clinically significant concurrent illnesses * Females of childbearing potential not using birth control or breastfeeding * Prior radiation therapy \> 25% of the bone marrow * Symptomatic brain metastasis * History of Grade III/IV cardiac problems * History of major surgery within 14 days prior to being registered * Treatment with any investigational agent within 30 days prior to being registered for protocol therapy.

Locations (1)

Indiana University Cancer Center

Indianapolis, Indiana, United States

Outcomes

Primary Outcomes

To determine the objective response rate of imatinib in patients with c-kit or PDGF positive thymic carcinoma.

Time frame: baseline through progression

To determine the duration of remission of patients with thymic carcinoma treated with imatinib.

Time frame: baseline through progression

To determine the toxicity of imatinib in this patient population.

Time frame: baseline through end of study

To determine the incidence of kit mutations in thymic malignancies.

Time frame: baseline

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.